Where is Toxotech located?

Toxotech is headquartered in Sweden.

Where does Toxotech rank among its competitors?

Toxotech ranks 632nd amongst 534 active competitors, of which 169 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $372M in Jul, 2025.

Who are the top competitors of Toxotech?

Toxotech's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in July, 2025.

Toxotech - 2026 Company Profile & Competitors

Company Details

Developer of engineered botulinum neurotoxin therapeutics for treating neurological disorders. The research focuses on modifying toxin structures to enhance receptor engagement and neuronal targeting. These synthetic molecules are designed to achieve sustained therapeutic effects for patients with neuromuscular and neurological conditions. The development process utilizes insights into protein structure and receptor interaction to create platforms for biotherapeutic applications.

Website: www.toxotech.se/
Email ID: *****@toxotech.se
Phone Number: +46 **********

Key Metrics

Founded Year

2020

Location

Sweden

Stage

Unfunded

Ranked

632^nd among 632 competitors

Similar Companies

Keros Therapeutics & 50 more

View Toxotech's full profile

Toxotech has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Toxotech include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Toxotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	69/100
5th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
6th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 10 others	68/100
7th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	BB Biotech, Avalon Ventures & 5 others	68/100
8th	Neumora 2020, Watertown (United States), Public	Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders	$612M	Arch Venture Partners, F-Prime Capital & 19 others	67/100
9th	Keros Therapeutics 2016, Lexington (United States), Public	Developer of small molecules to treat hematologic and musculoskeletal disorders	$90M	Foresite Capital, Pontifax & 9 others	66/100
10th	PureTech Health 2005, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual & 1 others	66/100
632nd	Toxotech 2020, Sweden, Unfunded	Developer of engineered botulinum neurotoxin therapeutics for treating neurological disorders	-	-	-